• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cannabis Industry Investor Presentations Now Available for On-Demand Viewing

    9/13/21 8:43:00 AM ET
    $CLVR
    $GNRS
    $IMCC
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Business Services
    Finance
    Get the next $CLVR alert in real time by email

    Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view the presentations

    NEW YORK, Sept. 13, 2021 /CNW/ - Virtual Investor Conferences® and KCSA Strategic Communications today announced that the presentations from the September 8th & 9th Cannabis Industry Virtual lnvestor Conference are now available for on-demand viewing at VirtualInvestorConferences.com.

    REGISTER OR LOGIN NOW AT:  https://bit.ly/3BUC6w8

    All presentations will be available for 24/7 on-demand replay for 90 days. Investors, advisors and analysts may also download shareholder materials from the "virtual trade booth" for the next three weeks.

    Presentations:

    Presenting Company

    Ticker(s)

    Innocan Pharma Corp.

    ((INNPF, CSE:INNO)

    MariMed Inc.

    OTCQX: MRMD

    The Valens Company Inc.

    ((VLNCF, TSX:VLNS)

    Nova Cannabis Inc.

    ((NVACF, TSX:NOVC)

    InMed Pharmaceuticals Inc.

    Nasdaq: INM

    Vibe Growth Corp.

    ((VIBEF, CSE:VIBE)

    1933 Industries Inc.

    OTCQB: TGIFF | CSE: TGIF

    MediPharm Labs Corp.

    ((MEDIF, TSX:LABS)

    IM Cannabis Corp.

    ((IMCC, CSE:IMCC)

    NewLake Capital Partners, Inc.

    OTCQX: NLCP

    Aleafia Health Inc.

    ((ALEAF, TSX:AH)

    InterCure Ltd.

    ((INCR, TSX:INCR)

    Verano Holdings Corp.

    ((VRNOF, CSE:VRNO)

    Fire & Flower Holdings Corp.

    ((FFLWF, TSX:FAF)

    Delta 9 Cannabis Inc,

    ((DLTNF, TSX:DN)

    Clever Leaves Holdings Inc.

    (NASDAQ: CLVR, CLVRW)

    Australis Capital Inc.

    ((AUSAF, CSE:AUSA)

    Lowell Farms Inc.

    ((LOWLF, CSE:LOWL)

    Flower One Holdings Inc.

    ((FLOOF, CSE:FONE)

    Sugarbud Craft Growers Corp.

    ((SBUDF, TSXV:SUGR)

    Greenrose Acquisition Corp.

    ((GNRS, GNRSU, GNRSW))

    To facilitate investor relations scheduling, for more information about the program and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor ConferencesSM

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.



    A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group's suite of investor relations services specifically designed for more efficient Investor Access.  Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

    SOURCE VirtualInvestorConferences.com

    Cision View original content: http://www.newswire.ca/en/releases/archive/September2021/13/c3553.html

    Get the next $CLVR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLVR
    $GNRS
    $IMCC
    $INCR

    CompanyDatePrice TargetRatingAnalyst
    Intercure Ltd.
    $INCR
    5/18/2022$13.00Speculative Buy → Buy
    Canaccord Genuity
    Clever Leaves Holdings Inc.
    $CLVR
    12/23/2021$12.00 → $10.00Buy
    Canaccord Genuity
    InMed Pharmaceuticals Inc.
    $INM
    11/29/2021$6.00Buy
    HC Wainwright & Co.
    Clever Leaves Holdings Inc.
    $CLVR
    11/12/2021$13.00 → $12.00Buy
    Canaccord Genuity
    IM Cannabis Corp.
    $IMCC
    10/5/2021$8.00Buy
    ROTH Capital
    Clever Leaves Holdings Inc.
    $CLVR
    7/27/2021$13.00Buy
    Canaccord Genuity
    Clever Leaves Holdings Inc.
    $CLVR
    7/23/2021Market Perform
    Cowen
    IM Cannabis Corp.
    $IMCC
    7/14/2021Buy
    Desjardins
    More analyst ratings

    $CLVR
    $GNRS
    $IMCC
    $INCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements

    Vancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), today announce that it had received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on June 3, 2026 informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on Nasdaq.As previously disclosed, the Company was notified by Nasdaq on March 27, 2026 that its common shares had failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. Nasdaq has now determined that the closing bid price of the Com

    6/4/26 5:00:00 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IM Cannabis Raises US$225,000 of Gross Proceeds in Convertible Note Financing

    TORONTO and GLIL YAM, Israel, June 3, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), a medical cannabis company with operations in Israel and Germany, today announced the closing of a US$225,000 convertible note financing in a private placement with an institutional investor (the "Lender"). Pursuant to a note purchase agreement between the Company and Lender dated June 3, 2026 (the "June Note Purchase Agreement"), the Company issued the Lender a note in the principal amount of US$225,000, with an original issuance discount of 10% (the "June Note").The June Note bears interest at a rate of 8% per annum, increasing to 14% upon the occurrence and continuation of

    6/3/26 4:01:00 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    /C O R R E C T I O N -- InMed Pharmaceuticals/

    In the news release, InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies, issued 19-May-2026 by InMed Pharmaceuticals over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies Mentari's parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapiesConcurrent oversubscribed US$290 million private placement of Mentari expected to fund company o

    5/19/26 8:00:00 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLVR
    $GNRS
    $IMCC
    $INCR
    SEC Filings

    View All

    SEC Form 6-K filed by IM Cannabis Corp.

    6-K - IM Cannabis Corp. (0001792030) (Filer)

    6/3/26 4:30:22 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 425 filed by InMed Pharmaceuticals Inc.

    425 - InMed Pharmaceuticals Inc. (0001728328) (Subject)

    5/19/26 10:34:05 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InMed Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure

    8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)

    5/19/26 10:32:30 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLVR
    $GNRS
    $IMCC
    $INCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    InterCure upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded InterCure from Speculative Buy to Buy and set a new price target of $13.00

    5/18/22 7:21:05 AM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity reiterated coverage on Clever Leaves Holdings with a new price target

    Canaccord Genuity reiterated coverage of Clever Leaves Holdings with a rating of Buy and set a new price target of $10.00 from $12.00 previously

    12/23/21 7:40:56 AM ET
    $CLVR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on InMed Pharmaceuticals with a new price target

    HC Wainwright & Co. initiated coverage of InMed Pharmaceuticals with a rating of Buy and set a new price target of $6.00

    11/29/21 6:20:24 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLVR
    $GNRS
    $IMCC
    $INCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Adar1 Capital Management, Llc bought $721,548 worth of shares (468,551 units at $1.54) (SEC Form 4)

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    5/21/26 5:08:05 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hull Andrew bought $14,625 worth of shares (37,500 units at $0.39), increasing direct ownership by 4,947% to 38,258 units (SEC Form 4)

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    2/22/24 1:38:46 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adams Eric A bought $14,922 worth of shares (41,600 units at $0.36), increasing direct ownership by 1,763% to 43,959 units (SEC Form 4)

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    2/21/24 2:58:17 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLVR
    $GNRS
    $IMCC
    $INCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Adar1 Capital Management, Llc bought $721,548 worth of shares (468,551 units at $1.54) (SEC Form 4)

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    5/21/26 5:08:05 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Adar1 Capital Management, Llc claimed ownership of 331,449 shares (SEC Form 3)

    3 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    5/21/26 4:51:08 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Rabinovich Alexander

    3 - Intercure Ltd. (0001857030) (Issuer)

    4/20/26 4:01:14 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLVR
    $GNRS
    $IMCC
    $INCR
    Leadership Updates

    Live Leadership Updates

    View All

    IM Cannabis Announces the Appointment of Mr. Alon Dayan to its Board of Directors

    TORONTO and GLIL YAM, Israel, Jan. 5, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), medical cannabis company with operations in Israel and Germany, announced today that Mr. Alon Dayan has been appointed to the Company's board of directors effective December 31, 2025. Mr. Dayan, who is currently the Chief Executive Officer of KeepZone AI Inc., a position he has held since 2025, brings over 15 years of executive experience in the homeland security technology sector, with a proven track record of founding and scaling innovative companies focused on systems integration, secure communications, and international business development. As the founder and Chief Execu

    1/5/26 8:55:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Appoints Asi Levi as Chief Financial Officer

    TORONTO and GLIL YAM, Israel, Dec. 12, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced, further to its press release dated October 29, 2025, the appointment of Asi Levi, CPA, as the Company's Chief Financial Officer ("CFO"), effective immediately, to replace Uri Birenberg. Mr. Levi has over 15 years of experience in finance and controlling roles, including serving as Chief Financial Officer of Water Ways Technologies Inc. and DekelOil CI, part of Dekel Agri-Vision Plc and as Controller of SciSparc Ltd. and A2Z Cust2Mate Solutions Corp. He has overseen fundraising efforts

    12/12/25 4:01:00 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors

    TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ --  IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC) (CSE:IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company's board of directors (the "Board") effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company's commitment to driving growth while focusing on sustainable profitability. "We are thrilled to welcome Shmulik to our Board of Directors," said Oren Shuster, Chief Executive Officer of

    9/11/24 8:30:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CLVR
    $GNRS
    $IMCC
    $INCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by InMed Pharmaceuticals Inc.

    SC 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)

    11/14/24 4:36:01 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by InMed Pharmaceuticals Inc.

    SC 13G - InMed Pharmaceuticals Inc. (0001728328) (Subject)

    11/12/24 1:44:16 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Clever Leaves Holdings Inc. (Amendment)

    SC 13D/A - Clever Leaves Holdings Inc. (0001819615) (Subject)

    5/21/24 8:03:23 PM ET
    $CLVR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLVR
    $GNRS
    $IMCC
    $INCR
    Financials

    Live finance-specific insights

    View All

    IM Cannabis Corp. Announces First Quarter 2026 Financial Results

    TORONTO and GLIL YAM, Israel, May 13, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC), a medical cannabis company with operations in Israel and Germany, today announced its financial results for the first quarter ended March 31, 2026. All amounts were reported in Canadian dollars, unless otherwise stated. For the three months ended March 31, 2026, the Company recorded revenues of $8.7 million, gross profit of $1.4 million, operating loss of $1.7 million, and a net loss of $2.5 million, or $0.38 per share. The Company also continued to advance its co

    5/13/26 4:01:00 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Reports Third Quarter 2025 Financial Results

    TORONTO and GLIL YAM, Israel, Nov. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC), an international medical cannabis company, announced its financial results today for the third quarter and nine months ended September 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter and nine months ended September 30, 2024, unless otherwise stated. Q3 2025 Financial Highlights:  Consistent Revenue for Q3 2025 and 2024 of $13.9 million.13% Gross profit decrease vs. Q3 2024 of $2.7 million vs. $3.1 million.13% Gross Margin decrease vs. Q3 2024 of 20% vs. 23%. $3.1 million One time goodwill and intangible asset impairment in Q3 2025 Operating

    11/13/25 9:00:00 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care

    IM Cannabis Announces Warrant Amendments and Form F-3 Resale Registration Statement Filing

    TORONTO and GLIL YAM, Israel, Aug. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ:IMCC), a leading medical cannabis company with operations in Israel and Germany, announces that it has agreed with holders (each, a "Holder") of common share purchase warrants ("November 2024 Warrants") issued by the Company as part of its non-brokered private placement offering which closed on November 12, 2024 to: (x) reduce the exercise price of each November 2024 Warrant from C$4.32 to C$3.43; and (y) extend the expiration date of each November 2024 Warrant from November 12, 2026 to July 31, 2030 (together, the "Transaction"). Form F-3 Resale Registration Statement The

    8/13/25 4:01:00 PM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care